期刊文献+

他汀类药物的临床应用进展 被引量:6

Progress in Clinical Appilication of Statins
暂未订购
导出
摘要 他汀类药物是目前临床上应用最多的调脂药。近年来不断有证据表明,他汀类药物不仅具有调脂作用,而且可以改善内皮细胞功能,减少动脉硬化斑块中的炎性成分,具有抗炎、抗动脉粥样硬化的作用。研究证实,他汀类调脂药在冠状动脉粥样硬化性心脏病一级预防、二级预防及心脏围术期具有广泛的心血管保护作用。另外,也有研究试图探索他汀类药物对于心房颤动、心力衰竭等其他心血管疾病是否也同样具有保护作用。同时,由于其在临床的广泛的、大剂量的应用,其安全性也日益受到重视。 Statins is currently the most commonly used lipid-lowering drug. Recently, accumulating evi- dence suggests that statins not only affects lipid metabolism but also alters endothelial function,and decreases the inflammatory component of plaques, thus has the effect of anti-inflammation and anti- atherosclerosis. Evi- dence suggests that statins has general cardioproteetive effects as primary, secondary prevention of coronary heart disease, and peri-corunary intervention of coronary atherosclerotic heart disease. Other researches explored whether it has the same effect on atrial fibrillation, heart failure. Besides, due to its wide and high- dose application, its adverse reaction has also been concerned.
出处 《医学综述》 2013年第11期2051-2054,共4页 Medical Recapitulate
关键词 他汀类药物 动脉粥样硬化 冠状动脉粥样硬化性心脏病 Statins Atherosclerosis Coronary atherosclerotic heart disease
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献348

同被引文献47

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部